a non-silencing control sequence Search Results


90
RNAi Co Ltd a non-silencing control sequence
A Non Silencing Control Sequence, supplied by RNAi Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+non-silencing+control+sequence/a+non+silencing+control+sequence/pmc04556056-236-1-4
Average 90 stars, based on 1 article reviews
a non-silencing control sequence - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma a nonsilencing sequence-expressing lentivirus (sh-nc) (5-ttctccgaacgtgtcacgtttc-3)
A Nonsilencing Sequence Expressing Lentivirus (Sh Nc) (5 Ttctccgaacgtgtcacgtttc 3), supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+non-silencing+control+sequence/a+nonsilencing+sequence+expressing+lentivirus++sh+nc+++5+ttctccgaacgtgtcacgtttc+3+/pmc05385397-36-10-19
Average 90 stars, based on 1 article reviews
a nonsilencing sequence-expressing lentivirus (sh-nc) (5-ttctccgaacgtgtcacgtttc-3) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Genechem nonsilencing control sequence
Nonsilencing Control Sequence, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+non-silencing+control+sequence/nonsilencing+control+sequence/10__3727_slash_096504016x14747253292210-50-10-21
Average 90 stars, based on 1 article reviews
nonsilencing control sequence - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Kaneka Corp non-silencing control sequence sirna
A549 and H358 cells were incubated with transfection reagent in the absence of any <t>siRNA</t> (first and second triplets or bands), transfected <t>with</t> <t>TIMP-1</t> siRNA (TIMP-1 si; third and fourth triplets or bands), or non-silencing siRNA (non si, fifth and sixth triplet or bands) for 24 h in DMEM containing 10% FCS. Subsequently, cells were washed and treated with vehicle or 1 µM cisplatin for 48 h in serum-free DMEM prior to collection of CM. ( A ) and ( C ), HUVECs suspended in CM from A549 ( A ) or H358 ( C ) cells were subjected to the upper chambers to quantify migration (black bars) or were used in the viability assay (WST-1, white bars) following a further 24-h incubation. Tube formation assays were performed after a 2-h incubation of HUVECs with the indicated CM (grey bars). ( B ) and ( D ), Monitoring of TIMP-1 was performed in parallel using CM obtained from A549 ( B ) or H358 ( D ) cells. Western blot images are representative of each experiment. Values above the blots are the mean ± SEM and represent alterations in TIMP-1 protein levels in CM in comparison with vehicle-treated cells (set as 100%), according to densitometric analyses. Western blotting analysis of TIMP-1 in CM was supplemented with β-actin analysis of the respective cell lysates. Values are the mean ± SEM of n = 3 ( A , migration and tube formation, B , C ), n = 4 ( D ) or n = 6 ( A , viability). ** p < 0.01, *** p < 0.001 vs. corresponding vehicle control; ## p < 0.01, ### p < 0.001 vs. the respective cisplatin-treated group without siRNA, one-way ANOVA plus a post-hoc Bonferroni test.
Non Silencing Control Sequence Sirna, supplied by Kaneka Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+non-silencing+control+sequence/non+silencing+control+sequence+sirna/pmc06183343-222-35-40
Average 90 stars, based on 1 article reviews
non-silencing control sequence sirna - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Bioservice Scientific Laboratories control non-silencing sequence
A549 and H358 cells were incubated with transfection reagent in the absence of any <t>siRNA</t> (first and second triplets or bands), transfected <t>with</t> <t>TIMP-1</t> siRNA (TIMP-1 si; third and fourth triplets or bands), or non-silencing siRNA (non si, fifth and sixth triplet or bands) for 24 h in DMEM containing 10% FCS. Subsequently, cells were washed and treated with vehicle or 1 µM cisplatin for 48 h in serum-free DMEM prior to collection of CM. ( A ) and ( C ), HUVECs suspended in CM from A549 ( A ) or H358 ( C ) cells were subjected to the upper chambers to quantify migration (black bars) or were used in the viability assay (WST-1, white bars) following a further 24-h incubation. Tube formation assays were performed after a 2-h incubation of HUVECs with the indicated CM (grey bars). ( B ) and ( D ), Monitoring of TIMP-1 was performed in parallel using CM obtained from A549 ( B ) or H358 ( D ) cells. Western blot images are representative of each experiment. Values above the blots are the mean ± SEM and represent alterations in TIMP-1 protein levels in CM in comparison with vehicle-treated cells (set as 100%), according to densitometric analyses. Western blotting analysis of TIMP-1 in CM was supplemented with β-actin analysis of the respective cell lysates. Values are the mean ± SEM of n = 3 ( A , migration and tube formation, B , C ), n = 4 ( D ) or n = 6 ( A , viability). ** p < 0.01, *** p < 0.001 vs. corresponding vehicle control; ## p < 0.01, ### p < 0.001 vs. the respective cisplatin-treated group without siRNA, one-way ANOVA plus a post-hoc Bonferroni test.
Control Non Silencing Sequence, supplied by Bioservice Scientific Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+non-silencing+control+sequence/control+non+silencing+sequence/pm19118217-314-26-33
Average 90 stars, based on 1 article reviews
control non-silencing sequence - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
ViraQuest Inc recombinant replication-deficient adenoviruses encoding the small interfering (si) rna sequence for trpv4 and control nonsilencing sirna
A549 and H358 cells were incubated with transfection reagent in the absence of any <t>siRNA</t> (first and second triplets or bands), transfected <t>with</t> <t>TIMP-1</t> siRNA (TIMP-1 si; third and fourth triplets or bands), or non-silencing siRNA (non si, fifth and sixth triplet or bands) for 24 h in DMEM containing 10% FCS. Subsequently, cells were washed and treated with vehicle or 1 µM cisplatin for 48 h in serum-free DMEM prior to collection of CM. ( A ) and ( C ), HUVECs suspended in CM from A549 ( A ) or H358 ( C ) cells were subjected to the upper chambers to quantify migration (black bars) or were used in the viability assay (WST-1, white bars) following a further 24-h incubation. Tube formation assays were performed after a 2-h incubation of HUVECs with the indicated CM (grey bars). ( B ) and ( D ), Monitoring of TIMP-1 was performed in parallel using CM obtained from A549 ( B ) or H358 ( D ) cells. Western blot images are representative of each experiment. Values above the blots are the mean ± SEM and represent alterations in TIMP-1 protein levels in CM in comparison with vehicle-treated cells (set as 100%), according to densitometric analyses. Western blotting analysis of TIMP-1 in CM was supplemented with β-actin analysis of the respective cell lysates. Values are the mean ± SEM of n = 3 ( A , migration and tube formation, B , C ), n = 4 ( D ) or n = 6 ( A , viability). ** p < 0.01, *** p < 0.001 vs. corresponding vehicle control; ## p < 0.01, ### p < 0.001 vs. the respective cisplatin-treated group without siRNA, one-way ANOVA plus a post-hoc Bonferroni test.
Recombinant Replication Deficient Adenoviruses Encoding The Small Interfering (Si) Rna Sequence For Trpv4 And Control Nonsilencing Sirna, supplied by ViraQuest Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+non-silencing+control+sequence/recombinant+replication+deficient+adenoviruses+encoding+the+small+interfering++si++rna+sequence+for+trpv4+and+control+nonsilencing+sirna/pmc02576139-69-2-29
Average 90 stars, based on 1 article reviews
recombinant replication-deficient adenoviruses encoding the small interfering (si) rna sequence for trpv4 and control nonsilencing sirna - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Shanghai GenePharma non-silencing control sequence (si-con)
A549 and H358 cells were incubated with transfection reagent in the absence of any <t>siRNA</t> (first and second triplets or bands), transfected <t>with</t> <t>TIMP-1</t> siRNA (TIMP-1 si; third and fourth triplets or bands), or non-silencing siRNA (non si, fifth and sixth triplet or bands) for 24 h in DMEM containing 10% FCS. Subsequently, cells were washed and treated with vehicle or 1 µM cisplatin for 48 h in serum-free DMEM prior to collection of CM. ( A ) and ( C ), HUVECs suspended in CM from A549 ( A ) or H358 ( C ) cells were subjected to the upper chambers to quantify migration (black bars) or were used in the viability assay (WST-1, white bars) following a further 24-h incubation. Tube formation assays were performed after a 2-h incubation of HUVECs with the indicated CM (grey bars). ( B ) and ( D ), Monitoring of TIMP-1 was performed in parallel using CM obtained from A549 ( B ) or H358 ( D ) cells. Western blot images are representative of each experiment. Values above the blots are the mean ± SEM and represent alterations in TIMP-1 protein levels in CM in comparison with vehicle-treated cells (set as 100%), according to densitometric analyses. Western blotting analysis of TIMP-1 in CM was supplemented with β-actin analysis of the respective cell lysates. Values are the mean ± SEM of n = 3 ( A , migration and tube formation, B , C ), n = 4 ( D ) or n = 6 ( A , viability). ** p < 0.01, *** p < 0.001 vs. corresponding vehicle control; ## p < 0.01, ### p < 0.001 vs. the respective cisplatin-treated group without siRNA, one-way ANOVA plus a post-hoc Bonferroni test.
Non Silencing Control Sequence (Si Con), supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+non-silencing+control+sequence/non+silencing+control+sequence++si+con+/pm27432753-50-33-40
Average 90 stars, based on 1 article reviews
non-silencing control sequence (si-con) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
RNAi Co Ltd nonsilencing control sequence
A549 and H358 cells were incubated with transfection reagent in the absence of any <t>siRNA</t> (first and second triplets or bands), transfected <t>with</t> <t>TIMP-1</t> siRNA (TIMP-1 si; third and fourth triplets or bands), or non-silencing siRNA (non si, fifth and sixth triplet or bands) for 24 h in DMEM containing 10% FCS. Subsequently, cells were washed and treated with vehicle or 1 µM cisplatin for 48 h in serum-free DMEM prior to collection of CM. ( A ) and ( C ), HUVECs suspended in CM from A549 ( A ) or H358 ( C ) cells were subjected to the upper chambers to quantify migration (black bars) or were used in the viability assay (WST-1, white bars) following a further 24-h incubation. Tube formation assays were performed after a 2-h incubation of HUVECs with the indicated CM (grey bars). ( B ) and ( D ), Monitoring of TIMP-1 was performed in parallel using CM obtained from A549 ( B ) or H358 ( D ) cells. Western blot images are representative of each experiment. Values above the blots are the mean ± SEM and represent alterations in TIMP-1 protein levels in CM in comparison with vehicle-treated cells (set as 100%), according to densitometric analyses. Western blotting analysis of TIMP-1 in CM was supplemented with β-actin analysis of the respective cell lysates. Values are the mean ± SEM of n = 3 ( A , migration and tube formation, B , C ), n = 4 ( D ) or n = 6 ( A , viability). ** p < 0.01, *** p < 0.001 vs. corresponding vehicle control; ## p < 0.01, ### p < 0.001 vs. the respective cisplatin-treated group without siRNA, one-way ANOVA plus a post-hoc Bonferroni test.
Nonsilencing Control Sequence, supplied by RNAi Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+non-silencing+control+sequence/nonsilencing+control+sequence/pm26330114-235-1-4
Average 90 stars, based on 1 article reviews
nonsilencing control sequence - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Genechem non-silencing control sequence
A549 and H358 cells were incubated with transfection reagent in the absence of any <t>siRNA</t> (first and second triplets or bands), transfected <t>with</t> <t>TIMP-1</t> siRNA (TIMP-1 si; third and fourth triplets or bands), or non-silencing siRNA (non si, fifth and sixth triplet or bands) for 24 h in DMEM containing 10% FCS. Subsequently, cells were washed and treated with vehicle or 1 µM cisplatin for 48 h in serum-free DMEM prior to collection of CM. ( A ) and ( C ), HUVECs suspended in CM from A549 ( A ) or H358 ( C ) cells were subjected to the upper chambers to quantify migration (black bars) or were used in the viability assay (WST-1, white bars) following a further 24-h incubation. Tube formation assays were performed after a 2-h incubation of HUVECs with the indicated CM (grey bars). ( B ) and ( D ), Monitoring of TIMP-1 was performed in parallel using CM obtained from A549 ( B ) or H358 ( D ) cells. Western blot images are representative of each experiment. Values above the blots are the mean ± SEM and represent alterations in TIMP-1 protein levels in CM in comparison with vehicle-treated cells (set as 100%), according to densitometric analyses. Western blotting analysis of TIMP-1 in CM was supplemented with β-actin analysis of the respective cell lysates. Values are the mean ± SEM of n = 3 ( A , migration and tube formation, B , C ), n = 4 ( D ) or n = 6 ( A , viability). ** p < 0.01, *** p < 0.001 vs. corresponding vehicle control; ## p < 0.01, ### p < 0.001 vs. the respective cisplatin-treated group without siRNA, one-way ANOVA plus a post-hoc Bonferroni test.
Non Silencing Control Sequence, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a+non-silencing+control+sequence/non+silencing+control+sequence/pm25680556-45-13-24
Average 90 stars, based on 1 article reviews
non-silencing control sequence - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


A549 and H358 cells were incubated with transfection reagent in the absence of any siRNA (first and second triplets or bands), transfected with TIMP-1 siRNA (TIMP-1 si; third and fourth triplets or bands), or non-silencing siRNA (non si, fifth and sixth triplet or bands) for 24 h in DMEM containing 10% FCS. Subsequently, cells were washed and treated with vehicle or 1 µM cisplatin for 48 h in serum-free DMEM prior to collection of CM. ( A ) and ( C ), HUVECs suspended in CM from A549 ( A ) or H358 ( C ) cells were subjected to the upper chambers to quantify migration (black bars) or were used in the viability assay (WST-1, white bars) following a further 24-h incubation. Tube formation assays were performed after a 2-h incubation of HUVECs with the indicated CM (grey bars). ( B ) and ( D ), Monitoring of TIMP-1 was performed in parallel using CM obtained from A549 ( B ) or H358 ( D ) cells. Western blot images are representative of each experiment. Values above the blots are the mean ± SEM and represent alterations in TIMP-1 protein levels in CM in comparison with vehicle-treated cells (set as 100%), according to densitometric analyses. Western blotting analysis of TIMP-1 in CM was supplemented with β-actin analysis of the respective cell lysates. Values are the mean ± SEM of n = 3 ( A , migration and tube formation, B , C ), n = 4 ( D ) or n = 6 ( A , viability). ** p < 0.01, *** p < 0.001 vs. corresponding vehicle control; ## p < 0.01, ### p < 0.001 vs. the respective cisplatin-treated group without siRNA, one-way ANOVA plus a post-hoc Bonferroni test.

Journal: Oncotarget

Article Title: The antiangiogenic action of cisplatin on endothelial cells is mediated through the release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells

doi: 10.18632/oncotarget.25954

Figure Lengend Snippet: A549 and H358 cells were incubated with transfection reagent in the absence of any siRNA (first and second triplets or bands), transfected with TIMP-1 siRNA (TIMP-1 si; third and fourth triplets or bands), or non-silencing siRNA (non si, fifth and sixth triplet or bands) for 24 h in DMEM containing 10% FCS. Subsequently, cells were washed and treated with vehicle or 1 µM cisplatin for 48 h in serum-free DMEM prior to collection of CM. ( A ) and ( C ), HUVECs suspended in CM from A549 ( A ) or H358 ( C ) cells were subjected to the upper chambers to quantify migration (black bars) or were used in the viability assay (WST-1, white bars) following a further 24-h incubation. Tube formation assays were performed after a 2-h incubation of HUVECs with the indicated CM (grey bars). ( B ) and ( D ), Monitoring of TIMP-1 was performed in parallel using CM obtained from A549 ( B ) or H358 ( D ) cells. Western blot images are representative of each experiment. Values above the blots are the mean ± SEM and represent alterations in TIMP-1 protein levels in CM in comparison with vehicle-treated cells (set as 100%), according to densitometric analyses. Western blotting analysis of TIMP-1 in CM was supplemented with β-actin analysis of the respective cell lysates. Values are the mean ± SEM of n = 3 ( A , migration and tube formation, B , C ), n = 4 ( D ) or n = 6 ( A , viability). ** p < 0.01, *** p < 0.001 vs. corresponding vehicle control; ## p < 0.01, ### p < 0.001 vs. the respective cisplatin-treated group without siRNA, one-way ANOVA plus a post-hoc Bonferroni test.

Article Snippet: Subsequently, RNA suspension buffer without siRNA (first and second triplet in Figure and ; first and second lane in the western blots in Figure and ), with TIMP-1 siRNA (Qiagen, Hilden, Germany), or with a non-silencing control sequence siRNA (nonsi; Eurogentec [Cologne, Germany]) were added.

Techniques: Incubation, Transfection, Migration, Viability Assay, Western Blot